dr. bruix discusses progress of second-line treatment in hcc
Published 7 years ago • 15 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
2:04
dr. bruix on regorafenib in second-line hcc
-
1:35
dr. bruix discusses the success of regorafenib in hcc
-
2:20
dr. bruix discusses the updated findings of the resorce trial in hcc
-
6:39
emerging second-line therapies in hcc
-
1:28
dr. jordi bruix on efficacy and safety of regorafenib in hcc after sorafenib
-
2:31
dr. bruix on the phase iii resorce trial in hcc
-
8:29
incorporating regorafenib in the hcc treatment landscape
-
1:47
dr. jordi bruix on the impact regorafenib will have on liver cancer treatment
-
1:38
dr. el-khoueiry discusses research on biomarkers in hcc
-
7:35
diagnosing hcc: when a biopsy is needed
-
1:08
dr. bendell on fda approval of regorafenib in liver cancer
-
5:26
hcc whiteboard #1: the epidemiology of hepatocellular carcinoma and current standard of care
-
1:02
dr. kudo discusses tace plus sorafenib in hcc
-
0:49
dr. daniele on impact of regorafenib in hcc
-
1:03
dr. musher discusses the role of regorafenib in advanced hcc
-
3:17
second-line systemic therapy in hcc
-
8:10
dosing strategies with sorafenib in hcc
-
2:18
dr. welling on checkmate-040 trial of nivolumab in hcc
-
1:15
dr. huey on the importance of patient selection in hcc